BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 32414074)

  • 1. Past, Present and Future of Epigenetics in Adrenocortical Carcinoma.
    Ettaieb M; Kerkhofs T; van Engeland M; Haak H
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32414074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment.
    Shariq OA; McKenzie TJ
    Ther Adv Chronic Dis; 2021; 12():20406223211033103. PubMed ID: 34349894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
    Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Interesting Case of Hepatic Adrenocortical Carcinoma.
    Permana H; Darmawan G; Ritonga E; Kusumawati M; Miftahurachman M; Soetedjo NN
    Acta Med Indones; 2018 Jul; 50(3):257-259. PubMed ID: 30333277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotane treatment for adrenocortical carcinoma: an overview.
    De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
    Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical review: Adrenocortical carcinoma: clinical update.
    Allolio B; Fassnacht M
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2027-37. PubMed ID: 16551738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical management of adrenocortical carcinoma.
    Ranvier GG; Inabnet WB
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):435-52. PubMed ID: 26038210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
    Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
    Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic dysregulation in adrenocortical carcinoma, a systematic review of the literature.
    Jonker PKC; Meyer VM; Kruijff S
    Mol Cell Endocrinol; 2018 Jul; 469():77-84. PubMed ID: 28830787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.
    Creemers SG; Hofland LJ; Korpershoek E; Franssen GJ; van Kemenade FJ; de Herder WW; Feelders RA
    Endocr Relat Cancer; 2016 Jan; 23(1):R43-69. PubMed ID: 26475053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary management of adrenocortical carcinoma.
    Zini L; Porpiglia F; Fassnacht M
    Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathobiology and genetics of adrenocortical carcinoma.
    Pittaway JFH; Guasti L
    J Mol Endocrinol; 2019 Feb; 62(2):R105-R119. PubMed ID: 30072419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging therapies for advanced adrenocortical carcinoma.
    Oncologist; ; . PubMed ID: 21212436
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.